4.6 Article

High Endothelial Venule Blood Vessels for Tumor-Infiltrating Lymphocytes Are Associated with Lymphotoxin β-Producing Dendritic Cells in Human Breast Cancer

期刊

JOURNAL OF IMMUNOLOGY
卷 191, 期 4, 页码 2001-2008

出版社

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1300872

关键词

-

资金

  1. Institut National du Cancer [2012-039]
  2. Fondation Reseau Innovations Therapeutiques en Cancerologie
  3. Region Midi-Pyrenees
  4. Fondation ARC pour la Recherche sur le Cancer [SL220110603471, ECL2010R00650]
  5. Ligue Nationale contre le Cancer
  6. Association Le Cancer du Sein, Parlons-en!

向作者/读者索取更多资源

Blood vessels and tumor angiogenesis are generally associated with tumor growth and poor clinical outcome of cancer patients. However, we recently discovered that some blood vessels present within the tumor microenvironment can be associated with favorable prognosis. These vessels, designated tumor high endothelial venules (HEVs), appear to facilitate tumor destruction by allowing high levels of lymphocyte infiltration into tumors. In this study, we investigated the mechanisms regulating HEV blood vessels in human breast cancer. We found that lymphotoxin beta was overexpressed in tumors containing high densities of HEVs (HEVhigh) and correlated to DC-LAMP, a marker of mature DCs. DCs were the main producers of lymphotoxin b in freshly resected HEVhigh breast tumor samples, and the density of DC-LAMP(+) DCs clusters was strongly correlated with the density of tumor HEVs, T and B cell infiltration, and favorable clinical outcome in a retrospective cohort of 146 primary invasive breast cancer patients. Densities of tumor HEVs and DC-LAMP(+) DCs were strongly reduced during breast cancer progression from in situ carcinoma to invasive carcinoma, suggesting that loss of tumor HEVs is a critical step during breast cancer progression. Finally, an increase in the infiltration of regulatory T cells was observed in HEVhigh breast tumors, indicating that tumor HEVs can develop in the presence of regulatory T cells. Together, our results support a key role for DCs and DC-derived lymphotoxin in the formation of tumor HEVs. These findings are important because novel therapeutic strategies based on the modulation of tumor HEVs could have a major impact on clinical outcome of cancer patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Otorhinolaryngology

Functional and oncological outcomes of salvage transoral robotic surgery: a comparative study

Pierre Gazda, Clement Gauche, Leonor Chaltiel, Emilien Chabrillac, Benjamin Vairel, Guillaume De Bonnecaze, Agnes Dupret-Bories, Thomas Filleron, Sebastien Vergez

Summary: This study confirms that survival and functional outcomes after salvage TORS are worse than in first line surgery.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2022)

Article Allergy

Targeting androgen signaling in ILC2s protects from IL-33-driven lung inflammation, independently of KLRG1

Eve Blanquart, Audrey Mandonnet, Marion Mars, Claire Cenac, Nina Anesi, Pascale Mercier, Christophe Audouard, Stephane Roga, Gilberto Serrano de Almeida, Charlotte L. Bevan, Jean-Philippe Girard, Lucette Pelletier, Sophie Laffont, Jean-Charles Guery

Summary: This study investigates the impact of androgens on the development and function of innate lymphoid cells in female lungs. The findings suggest that androgens negatively control innate lymphoid cell homeostasis and inflammation in a cell-intrinsic manner. The inhibitory receptor killer cell lectin-like receptor G1 is found to play a dispensable role in androgen-mediated inhibition of innate lymphoid cells.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Article Oncology

Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy

Assia Asrir, Claire Tardiveau, Juliette Coudert, Robin Laffont, Lucas Blanchard, Elisabeth Bellard, Krystle Veerman, Sarah Bettini, Fanny Lafouresse, Estefania Vina, Dorian Tarroux, Severine Roy, Isabelle Girault, Irma Molinaro, Frederic Martins, Jean-Yves Scoazec, Nathalie Ortega, Caroline Robert, Jean-Philippe Girard

Summary: Tumor-associated high endothelial venules (TA-HEVs) are crucial for recruiting lymphocytes into tumors, and their presence is associated with better response and survival in anti-PD-1/anti-CTLA-4 treatment. TA-HECs co-express specific proteins and selectins, which attract lymphocytes to infiltrate tumors. Understanding the mechanism of lymphocyte trafficking in cancer immunity and immunotherapy is important for improving treatment outcomes.

CANCER CELL (2022)

Article Oncology

Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience

Tina Lamy, Bastien Cabarrou, David Planchard, Xavier Quantin, Sophie Schneider, Michael Bringuier, Benjamin Besse, Nicolas Girard, Christos Chouaid, Thomas Filleron, Gaetane Simon, Capucine Baldini

Summary: This study compared the proportion of biomarker testing performed in older patients (>= 70 years old) and younger patients with non-squamous aNSCLC, showing no significant difference in testing frequency between the two age groups. Among older patients tested, 22% presented an EGFR mutation. These findings suggest that age is not a barrier to biomarker testing in patients with aNSCLC.

CANCERS (2022)

Meeting Abstract Oncology

Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)

Veronique Dieras, Elise Deluche, Amelie Lusque, Barbara Pistilli, Thomas Bachelot, Jean-Yves Pierga, Frederic Viret, Christelle Levy, Laura Salabert, Fanny Le Du, Florence Dalenc, Christelle Jouannaud, Laurence Venat-Bouvet, Jean-Philippe Jacquin, Xavier Durando, Thierry Petit, Celine Mahier -Ait Oukhatar, Thomas Filleron, Maria Fernanda Mosele, Magali Lacroix-Triki, Agnes Ducoulombier, Fabrice Andre

CANCER RESEARCH (2022)

Letter Oncology

Accelerated phase chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies

Leopoldine Lapierre, Charlotte Syrykh, Laetitia Largeaud, Bastien Cabarrou, Thomas Filleron, Lucie Oberic, Salim Kanoun, Lucie Coster, Camille Laurent, Benoit Branco, Noemie Gadaud, Christian Recher, Delphine Brechemier, Laurent Balardy, Francois Vergez, Loic Ysebaert, Martin Gauthier

HEMATOLOGICAL ONCOLOGY (2022)

Article Health Care Sciences & Services

A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials

Bastien Cabarrou, Eve Leconte, Patrick Sfumato, Jean-Marie Boher, Thomas Filleron

Summary: In a heterogeneous population, the novel two-stage stratified adaptive phase II design provides a useful alternative to classical designs, allowing for the identification of a subgroup of interest without significantly increasing sample size. The design maintains competitive statistical power, controls type I error rates, and has a high probability of detecting heterogeneity, making it relevant not only for older populations but also for other study populations and the development of targeted therapies based on biomarkers.

BMC MEDICAL RESEARCH METHODOLOGY (2022)

Article Oncology

Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations

William Jacot, Amelie Lusque, Cecile Vicier, Audrey Mailliez, Thibault de La Motte Rouge, Luc Cabel, Christelle Levy, Anne Patsouris, Isabelle Desmoulins, Lionel Uwer, Jean-Christophe Thery, Mathieu Robain, Olivier Caron, Olivier Tredan, Thomas Filleron, Jean-Sebastien Frenel, Suzette Delaloge

Summary: In this study, the authors investigated the efficacy of platinum-based chemotherapy (PtCT) in patients with metastatic breast cancer (MBC) with and without germline BRCA1 or BRCA2 mutations. The results showed that first-line PtCT was associated with better progression-free survival (PFS) and overall survival (OS) in patients with gBRCA1/2 mutations, but not in those without mutations. These findings highlight the importance of early gBRCA1/2 testing in MBC patients.

BRITISH JOURNAL OF CANCER (2022)

Article Pathology

CINSARC signature outperforms gold-standard TNM staging and consensus molecular subtypes for clinical outcome in stage II-III colorectal carcinoma

Anne-Cecile Brunac, Joanna Fourquet, Gaelle Perot, Marion Jaffrelot, Julie Meilleroux, Marie Danjoux, Thomas Filleron, Vincent Nicolai, Rosine Guimbaud, Samira Icher, Nadim Fares, Janick Selves, Frederic Chibon

Summary: The outcome of stage II-III colorectal cancer (CRC) varies greatly, and current therapeutic choices are based on TNM staging and a few additional biomarkers. However, a 67-gene expression prognostic signature called CINSARC has been developed and shown to have independent prognostic value in stage II-III CRC. This signature outperforms TNM staging and CMS classification in predicting recurrence-free and overall survival.

MODERN PATHOLOGY (2022)

Article Multidisciplinary Sciences

Genomics to select treatment for patients with metastatic breast cancer

Fabrice Andre, Thomas Filleron, Maud Kamal, Fernanda Mosele, Monica Arnedos, Florence Dalenc, Marie-Paule Sablin, Mario Campone, Herve Bonnefoi, Claudia Lefeuvre-Plesse, William Jacot, Florence Coussy, Jean-Marc Ferrero, George Emile, Marie-Ange Mouret-Reynier, Jean-Christophe Thery, Nicolas Isambert, Alice Mege, Philippe Barthelemy, Benoit You, Nawale Hajjaji, Ludovic Lacroix, Etienne Rouleau, Alicia Tran-Dien, Sandrine Boyault, Valery Attignon, Pierre Gestraud, Nicolas Servant, Christophe Le Tourneau, Linda Larbi Cherif, Isabelle Soubeyran, Filippo Montemurro, Alain Morel, Amelie Lusque, Marta Jimenez, Alexandra Jacquet, Anthony Goncalves, Thomas Bachelot, Ivan Bieche

Summary: Cancer progression is driven by genomic alterations. Genomic profiling can help select effective therapies. A study on HER2-non-overexpressing metastatic breast cancer patients showed that targeted therapies matched to genomic alterations can improve progression-free survival, especially for patients with BRCA1/2 mutations.

NATURE (2022)

Meeting Abstract Hematology

Improving Patient Selection for Phase I Trials in Hematology: An External Validation of the Gustave Roussy Scoring System at Toulouse University Cancer Institute, Oncopole (IUCT-O)

Noemie Gadaud, Carlos Gomez Roca, Loic Ysebaert, Aurore Perrot, Myriam Estrabaut, Muriel Poublanc, Iphigenie Korakis, Christian Recher, Jean Pierre Delord, Thomas Filleron, Pierre Bories

Article Oncology

Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)

Anne Laprie, Georges Noel, Leonor Chaltiel, Gilles Truc, Marie-Pierre Sunyach, Marie Charissoux, Nicolas Magne, Pierre Auberdiac, Julian Biau, Soleakhena Ken, Fatima Tensaouti, Jonathan Khalifa, Ingrid Sidibe, Franck-Emmanuel Roux, Laure Vieillevigne, Isabelle Catalaa, Sergio Boetto, Emmanuelle Uro-Coste, Stephane Supiot, Valerie Bernier, Thomas Filleron, Muriel Mounier, Muriel Poublanc, Pascale Olivier, Jean-Pierre Delord, Elizabeth Cohen-Jonathan-Moyal

Summary: MRSI-guided dose escalation in newly diagnosed GBM patients did not improve overall survival (OS).

NEURO-ONCOLOGY (2023)

Article Medicine, Research & Experimental

IL-33 acts as a costimulatory signal to generate alloreactive Th1 cells in graft-versus-host disease

Gaelen K. Dwyer, Lisa R. Mathews, Jose A. Villegas, Anna Lucas, Anne Gonzalez de Peredo, Bruce R. Blazar, Jean-Philippe Girard, Amanda C. Poholek, Sanjiv A. Luther, Warren Shlomchik, Heth R. Turnquist

Summary: In allogeneic hematopoietic stem cell transplantation (alloHCT), recipient conditioning releases damage-associated molecular patterns (DAMPs) that generate proinflammatory antigen-presenting cells (APCs) secreting IL-12, which drives the response of donor Th1 cells, leading to graft-versus-host disease (GVHD). However, there are other mechanisms through which alloreactive T cell responses are initiated by directly acting on donor CD4(+) T cells. Among these mechanisms, fibroblastic reticular cell-derived DAMP IL-33 plays a critical role by enhancing T cell expansion and differentiation through the activation of T cell signaling pathways in response to alloantigen, resulting in GVHD.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Article Biochemical Research Methods

Flow cytometry analysis of endothelial cells and subsets of exhausted CD8+ T cells in murine tumor models

Lucas Blanchard, Estefania Vina, Assia Asrir, Claire Tardiveau, Juliette Coudert, Robin Laffont, Dorian Tarroux, Sarah Bettini, Krystle Veerman, Fanny Lafouresse, Melanie Pichery, Emilie Mirey, Elisabeth Bellard, Nathalie Ortega, Jean-Philippe Girard

Summary: This article presents a protocol for flow cytometry analysis of endothelial cells (ECs) and CD8+ T cells in murine tumor models, including baseline and post-immunotherapy analysis. The protocol is valuable for studying rare subsets of cells that play critical roles in antitumor immunity.

STAR PROTOCOLS (2022)

暂无数据